Article
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
The New England journal of medicine - 3 Dec 2020
André Thierry, Shiu Kai-Keen, Kim Tae Won, Jensen Benny Vittrup, Jensen Lars Henrik, Punt Cornelis, Smith Denis, Garcia-Carbonero Rocio, Benavides Manuel, Gibbs Peter, de la Fouchardiere Christelle, Rivera Fernando, Elez Elena, Bendell Johanna, Le Dung T, Yoshino Takayuki, Van Cutsem Eric, Yang Ping, Farooqui Mohammed Z H, Marinello Patricia, Diaz Luis A
Abstract excerpt
BACKGROUND: Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) tumors after previous therapy. The efficacy of PD-1 blockade as compared with chemotherapy as first-line therapy for MSI-H-dMMR advanced or metastatic colorectal cancer is unknown. METHODS: In this phase 3, open-label trial, 307 patients with metastatic MSI-H-dMMR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.